In collaboration with Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, the Transplant and Cellular Therapy Program at Rutgers Cancer Institute has been performing stem cell transplants since 1995. Ours is the only such program in New Jersey offered at an NCI-designated Comprehensive Cancer Center.
The Transplant and Cellular Therapy Program is accredited by the National Marrow Donor Program (NMDP) and the Foundation for the Accreditation of Cellular Therapy (FACT). It has been rated “Excellent” by the American College of Surgeons. We are a certified Gene Therapy Treatment Center for adults and children with sickle cell anemia and beta-thalassemia.
Our experts also offer stem cell transplantation for children, adolescents and young adults with cancer and blood disorders through our Pediatric Stem Cell Transplantation and Cellular Therapies Program.
What are Transplant and Cellular Therapies?
Transplant and Cellular Therapy is a specialized field of medicine that focuses on treating blood cancers and other illnesses using stem cell transplantation and innovative cellular therapies. This includes Chimeric Antigen Receptor T-cell (CAR T-cell) therapy, blood and marrow transplants (BMT), gene therapy, and more. The expert hematologists and oncologists on our Transplant and Cellular Therapy team are equipped to treat patients with a wide range of illnesses, including:
- Acute and chronic leukemias
- Myelodysplasic syndromes
- Myeloproliferative neoplasms
- Aplastic anemia and bone marrow failure syndromes
- Hodgkin and non-Hodgkin lymphomas
- Multiple myeloma
- Amyloidosis
- Germ cell tumors
- Sickle Cell Disease
- Thalassemia
Explore Our Leukemia, Lymphoma and Hematologic Malignancies Program
Learn more about the various blood cancers and hematologic diseases through our Leukemia, Lymphoma and Hematologic Malignancies Program. Our experts work together to provide the most effective and advanced treatments offered, many available only at NCI-designated Comprehensive Cancer Centers such as ours.
Available Treatment Options
Meet Our Team
Additional Resources
Related Articles and Press
CAR T-Cell Therapy via a Community Lens
Efforts to bring CAR T-cell therapy into the community must address logistical, operational, and educational barriers to improve access for all patients.
Transplant and Cell Therapy Program Awarded Accreditation by the Foundation for the Accreditation of Cellular Therapy
The Foundation for the Accreditation of Cellular Therapy (FACT) has once again awarded Rutgers Cancer Institute and Robert Wood Johnson University Hospital’s (RWJUH) Transplant and Cell Therapy Program accreditation under the FACT-JACIE International Standards for Hematopoietic Cellular Therapy.
Hematology/Oncology Data Showcase: 65th American Society of Hematology Annual Meeting and Exposition
Rutgers Cancer Institute and RWJBarnabas Health provide 36 oral and poster presentations that examine new advancements in the diagnosis, treatment, and management of blood cancers.
Why is CAR T-Cell Therapy So Exciting? Answers From an Expert
CAR T-cell immunotherapy is a cutting-edge treatment option for patients with adult aggressive B-cell non-Hodgkin lymphoma or acute lymphoblastic leukemia in children or young adults.
Leukemia and Transplant Team Collaboration
Neil Palmisiano, MD, MS discusses the collaboration process between teams when treating blood cancer patients using bone marrow transplants.
Hematology/Oncology Research at Rutgers Cancer Institute
Andrew Evens, DO, MBA, MSc discusses research advances in blood cancers and cellular therapy happening at Rutgers Cancer Institute.